InterVene, Inc. Company Profile

Background

Overview

InterVene, Inc. is a clinical-stage medical device company headquartered in Redwood City, California. The company specializes in developing innovative interventional solutions for chronic venous disease, particularly focusing on severe venous conditions affecting the legs. Their flagship product, the Recana™ Thrombectomy Catheter System, is designed to recanalize and restore patency in obstructed deep veins and venous stents, addressing clinical scenarios where existing treatments may be limited.

Mission and Vision

InterVene's mission is to provide life-changing options for patients suffering from chronic venous disease by advancing interventional therapies. The company's vision is to revolutionize the treatment of severe venous conditions through innovative, minimally invasive technologies that improve patient outcomes and quality of life.

Primary Area of Focus

The company's primary focus is on developing medical devices that address chronic venous insufficiency (CVI) and related complications, with an emphasis on deep vein thrombosis and venous stenting. Their products aim to offer effective solutions for venous obstructions that current therapies fail to address.

Industry Significance

InterVene operates within the medical device industry, specifically targeting the vascular and interventional sectors. The company's innovative approach to treating chronic venous disease positions it as a significant player in addressing a prevalent health issue affecting millions globally.

Key Strategic Focus

Core Objectives

Innovation in Treatment: Develop and commercialize advanced medical devices that provide effective solutions for chronic venous disease.

Patient-Centric Solutions: Enhance patient outcomes by offering minimally invasive therapies that address the underlying causes of venous obstructions.

Market Leadership: Establish a strong presence in the vascular medical device market through continuous innovation and strategic partnerships.

Specific Areas of Specialization

Deep Vein Thrombosis (DVT): Focus on developing devices that effectively treat DVT, a common cause of chronic venous insufficiency.

Venous Stenting: Create solutions that improve the efficacy and longevity of venous stents used in treating venous obstructions.

Key Technologies Utilized

Mechanical Thrombectomy Systems: Utilize advanced mechanical thrombectomy devices designed to recanalize obstructed veins.

Endovenous Valve Formation: Develop non-implantable, endovenous approaches to deep vein valve failure, allowing physicians to create new vein valves for patients.

Primary Markets Targeted

Healthcare Providers: Hospitals, clinics, and vascular specialists seeking advanced solutions for venous disease treatment.

Patients with Chronic Venous Disease: Individuals suffering from conditions like DVT, venous stasis ulcers, and other venous obstructions.

Financials and Funding

Funding History

InterVene has secured a total of $23.1 million in funding over three rounds.

Recent Funding Rounds

Series A: Led by RiverVest, with participation from Treo Ventures.

Notable Investors

RiverVest: A venture capital firm specializing in medical device investments.

Treo Ventures: An investment firm focusing on early-stage medical device companies.

Intended Utilization of Capital

The raised capital is intended to support the continued development and commercialization of InterVene's product pipeline, including the Recana™ Thrombectomy Catheter System, and to expand the company's operational capabilities.

Pipeline Development

Key Pipeline Candidates

Recana™ Thrombectomy Catheter System: An investigational device designed to treat venous in-stent restenosis and native vessel obstruction. Currently in the development stage, it is not FDA cleared or approved for clinical use.

Stages of Clinical Trials or Product Development

Development Stage: The Recana™ system is in the investigational phase, with ongoing research and development efforts.

Target Conditions

Venous In-Stent Restenosis: A condition where a previously placed stent in a vein becomes re-obstructed.

Native Vessel Obstruction: Blockages in veins not previously treated with stents.

Relevant Timelines for Anticipated Milestones

Clinical Trials: Specific timelines for clinical trials and product launch have not been publicly disclosed.

Technological Platform and Innovation

Proprietary Technologies

Recana™ Thrombectomy Catheter System: A mechanical thrombectomy device designed to recanalize obstructed veins. It is an investigational device limited by Federal (US) law to investigational use.

Significant Scientific Methods

Endovenous Valve Formation: A non-implantable, endovenous approach to deep vein valve failure, allowing physicians to create new vein valves for patients.

Leadership Team

Key Executive Profiles

Jeff Elkins: Chief Executive Officer (CEO). Former President & CEO of Veniti.

Michi Garrison: Vice President of Research & Development and Operations. Former VP of Research and Development at Silk Road Medical.

Leadership Changes

Specific details regarding recent leadership changes or appointments are not publicly disclosed.

Competitor Profile

Market Insights and Dynamics

The market for chronic venous disease treatments is growing, driven by an aging population and increasing prevalence of venous disorders. Innovative, minimally invasive therapies are in demand to address the limitations of current treatments.

Competitor Analysis

Hillrom: A global medical technology company offering a range of products, including those for vascular conditions.

Saluda Medical: Focuses on neuromodulation therapies but operates in the broader medical device space.

Bosch Healthcare Solutions: Provides medical devices and solutions, including those for vascular health.

Aveta System: Develops medical devices, including those targeting vascular conditions.

Strategic Collaborations and Partnerships

InterVene collaborates closely with physician partners to enhance interventional therapies for persistent venous challenges. Specific details regarding formal partnerships or alliances are not publicly disclosed.

Operational Insights

InterVene's integrated approach, encompassing research and development, manufacturing, quality systems, and regulatory affairs, allows for efficient product development and adaptation to emerging trends in the venous field.

Strategic Opportunities and Future Directions

The company aims to expand its product portfolio by developing additional devices targeting various aspects of venous disease treatment, leveraging its in-house capabilities to address unmet needs in the market.